Article contents
Prevalence of and Risk Factors for Vancomycin-Resistant Staphylococcus aureus Precursor Organisms in Southeastern Michigan
Published online by Cambridge University Press: 10 May 2016
Abstract
We assessed for vancomycin-resistant Staphylococcus aureus (VRSA) precursor organisms in southeastern Michigan, an area known to have VRSA. The prevalence was 2.5% (pSK41-positive methicillin-resistant S. aureus, 2009–2011) and 1.5% (Inc18-positive vancomycin-resistant Enterococcus, 2006–2013); Inc18 prevalence significantly decreased after 2009 (3.7% to 0.82%). Risk factors for pSK41 included intravenous vancomycin exposure.
Infect Control Hosp Epidemiol 2014;35(12):1531–1534
- Type
- Brief Report
- Information
- Copyright
- © 2014 by The Society for Healthcare Epidemiology of America. All rights reserved.
References
1.
Limbago, BM, Kallen, AJ, Zhu, W, Eggers, P, McDougal, LK, Albrecht, VS. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol
2014;52:998–1002.Google Scholar
2.
Centers for Disease Control and Prevention (CDC). CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). http://www.cdc.gov/HAI/settings/lab/vrsa_lab_search_containment.html. Accessed August 2, 2014.Google Scholar
3.
Zhu, W, Clark, N, Patel, JB. pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from Enterococcus faecalis to Staphylococcus aureus in vitro. Antimicrob Agents Chemother
2013;57:212–219.Google Scholar
4.
Zhu, W, Murray, PR, Huskins, WC, et al. Dissemination of an Enterococcus Inc18-like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother
2010;54:4314–4320.CrossRefGoogle ScholarPubMed
5.
Tosh, PK, Agolory, S, Strong, BL, et al. Prevalence and risk factors associated with vancomycin-resistant Staphylococcus aureus precursor organism colonization among patients with chronic lower-extremity wounds in southeastern Michigan. Infect Control Hosp Epidemiol
2013;34:954–960.Google Scholar
6.
McDougal, LK, Fosheim, GE, Nicholson, A, et al. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother
2010;54:3804–3811.Google Scholar
7.
Reyes, K, Malik, R, Moore, C, Donabedian, S, Perri, M, Johnson, L, Zervos, M. Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. J Clin Microbiol
2010;48:628–630.Google Scholar
8.
Melo-Cristino, J, Resina, C, Manuel, V, Lito, L, Ramirez, M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet
2013;382(9888):205.Google Scholar
9.
Rossi, F, Diaz, L, Wollam, A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med
2014;370(16):1524–1531.Google Scholar
- 7
- Cited by